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We previously demonstrated that hepatitis C virus (HCV) binds to human CD81 through the E2 glycoprotein. Therefore,
expression of the human CD81 molecule in transgenic mice was expected to provide a new tool to study HCV infection in
vivo, as the chimpanzee is the only species currently available as a laboratory animal model that can be infected with HCV.
We produced transgenic mice expressing the human CD81 protein in a wide variety of tissues. We confirmed binding of
recombinant E2 glycoprotein to the liver tissue as well as to thymocytes and splenic lymphocytes in the transgenic mice. We
inoculated chimpanzee plasma infected with HCV into these animals. None of these transgenic animals showed evidence of
viral replication. Furthermore, human CD81 transgenic mice that lack expression of endogenous mouse CD81 were also
resistant to HCV infection. We conclude that expression of human CD81 alone is insufficient to confer susceptibility to HCVKey Words: hepatitis C virus; CD81; transgenic mice; inf
INTRODUCTION
The host range of virus infection is determined by
several factors including surface receptors, cellular ma-
chinery for replication, translation and assembly of viral
proteins, and budding of infectious particles. It remains
unclear which of these factors is crucial for the restricted
host range of hepatitis C virus (HCV). Among various
species of laboratory animals, only the chimpanzee (Pan
troglodytes) is known to be susceptible to HCV infection.
Establishment of a new animal model for HCV infection
would therefore be extremely useful not only to study
pathogenesis of hepatitis C but also for the development
of vaccines and therapeutic drugs against this disease.
We previously demonstrated that chimpanzees protected
from HCV infection by immunization with recombinant
structural proteins of HCV produce neutralizing antibod-
ies which block binding between the cell surface and E2,
the major glycoprotein of HCV (Rosa et al., 1996). This
suggests that interaction between the E2 protein and a
cellular receptor for E2 may be crucial for virus particles
to enter into the target cell. Furthermore, we reported
that E2 binds to CD81 in a species-specific manner. We
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also demonstrated that a soluble form of the large extra-
cellular loop (LEL) of human CD81 enriched HCV
genomic RNA in vitro, suggesting that “bona fide” HCV
particles bind to LEL of the CD81 molecule. Moreover,
chimpanzee sera with neutralizing activity could block
binding of HCV to the soluble human CD81 molecule in
a dose-dependent manner (Pileri et al., 1998). These
findings strongly suggest that the human CD81 molecule
may act as a cellular receptor for HCV. However, there is
no direct proof that attachment of HCV particles to the
CD81 protein induces internalization of the virus followed
by replication of the viral genome. Although cultured
human cells express the CD81 molecule on their cell
surface, the lack of a robust in vitro culture system for
HCV hampers finding an answer to this question. There
may be several explanations of why human cells can
support replication of HCV in vitro only weakly and tran-
siently, if at all: (1) Culture conditions downregulate a
cellular factor indispensable for HCV replication machin-
ery; (2) Culture media lack important molecules that
support efficient replication of HCV; (3) Replication of
HCV requires a different cell type or an appropriate stage
of differentiation of the target cell that is not represented
in the cell lines tested.
Transgenesis is then a possible in vivo strategy to test
whether the human CD81 molecule is sufficient to conferinfection in the mouse. The presence of additional possible
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susceptibility to HCV infection to a naturally refractory
species such as the mouse.factor
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RESULTS
Transgene expression in human CD81 transgenic
mice
Human CD81 transgenic mice were produced under
the control of the CAG regulatory elements (Niwa et al.,
1991) to allow ubiquitous expression of the transgene. In
these mice, the transgene transcript was detected by
Northern blot hybridization (Fig. 1A). Judging from the
total amount of RNA detected by methylene blue staining
(Fig. 1B), although the spleen, brain, and testis ex-
pressed human CD81-specific RNA at relatively low lev-
els, the transgene transcript was detected in all organs
including the thymus, liver, heart, lung, and kidney.
We also tested transgene expression at the protein
level. In cryostat preparations of liver specimens, anti-
mouse immunoglobulin developed deep blue color on
the vascular surface of the hepatocyte due to residual
host immunoglobulin molecules (Fig. 2A). When we
added JS81, a monoclonal antibody against human CD81,
the transgenic liver preparation yielded red signals on
the biliary surface clearly distinguishable from the non-
transgenic liver preparation (Figs. 2B and 2C), indicating
that the human CD81 protein was expressed on the cell
surface of the transgenic hepatocytes. Although there
are other cell types such as endothelial cells, Kupfer
cells, and lipocytes in the liver, these cells are located in
the sinusoidal area. Our results therefore exclude the
possibility that the transgene is expressed only in these
nonhepatocytic lineage cells in the liver. We then tested
transgene expression in lymphoid organs by cytofluoro-
metric analysis. Although the specific RNA was pro-
duced at a much lower level, transgenic splenocytes and
thymocytes successfully expressed the human CD81
protein (Fig. 3A, a and b) at comparable levels. We also
detected the human CD81 protein on peripheral blood
lymphocytes (PBL) (Fig. 3B, b). Polymorphonuclear cells
(PMN) expressed the transgene at particularly high lev-
els (Fig. 3B, c). Altogether, the human CD81 transgenic
mice expressed the transgene ubiquitously. Transgene
expression did not affect the number of lymphocytes as
well as the B/T ratio, suggesting no gross alteration in
lymphocyte development (data not shown).
Binding of the recombinant HCV-E2 glycoprotein to
transgenic cells
We examined the binding of the recombinant HCV-E2
(I-E2715) protein to transgenic liver cells by immunohisto-
chemistry. I-E2715 bound specifically to transgenic liver
cells (Fig. 4B) but not to liver cells from nontransgenic
mice (Fig. 4A). The E2 binding on the transgenic liver
specimen was competed by preincubation with JS81 (Fig.
4C), indicating that I-E2715 bound directly to the human
CD81 molecule. We also checked for the binding of
I-E2715 to lymphocytes by cytofluorometry. The recombi-
nant I-E2715 protein also bound to the transgenic spleno-
cytes (Fig. 5A, a) and the thymocytes (Fig. 5A, b) as
expected. Intriguingly, although PBL from transgenic
mice failed to bind the I-E2715 protein (Fig. 5B, b), PMN in
the peripheral blood successfully bound to the recombi-
nant E2 glycoprotein (Fig. 5B, c).
Inoculation of human CD81 transgenic mice with
plasma infected with HCV
We prepared four series of intravenous inoculations
(20–2000 units of 50% chimp infectious dose, CID50) to
test susceptibility of human CD81 transgenic mice to
HCV infection in vivo. Each group contained three to four
animals, 3–6 months old at the time of inoculation; non-
transgenic littermates were also grouped and inoculated
with the same infectious plasma in the same manner as
negative controls. Sera of inoculated animals were col-
lected at regular intervals for up to 6 months to examine
the presence of HCV-specific RNA. No viral-specific se-
quence was amplified from sera of human CD81 trans-
genic mice or of normal littermates. Since the human
CD81 transgenic mice express high levels of the trans-
gene product in PMN (Fig. 3B, c), intravenously injected
virions might have been captured by PMN before they
reached the liver. To avoid this potential problem, we
also inoculated the infectious plasma intrahepatically.
Furthermore, we produced transgenic mice with the hu-
man CD81 gene under control of the albumin promoter,
which express the transgene in a liver-specific manner
(data not shown). These mice were also inoculated with
FIG. 1. Expression of the human CD81 transcript in organs of the
transgenic mice. (A) Hybridization with a human CD81 specific probe.
Ten to thirty micrograms of total RNA from a nontransgenic littermate
(Lane 1) and the human CD81 transgenic mouse (Lanes 2–9) were
separated on a formaldehyde–agarose gel and transferred on a nylon
membrane. Lane 1: liver; Lane 2: thymus; Lane 3: lung; Lane 4: heart;
Lane 5: spleen; Lane 6: kidney; Lane 7: brain; Lane 8: liver; Lane 9:
testis. The arrow indicates the position of the human CD81-specific
transcript. (B) Methylene blue staining to detect transferred RNA on the
hybridization filter.
188 MASCIOPINTO ET AL.
the same infectious plasma. These experiments again
yielded no evidence of viral replication.
We also asked whether these mice had built an im-
mune response against HCV, although they had not
given rise to whole virions. We performed enzyme-linked
immunosorbent assay (ELISA) and Western blot analysis
to detect antibodies in plasma of inoculated animals
against recombinant structural (core) and nonstructural
(NS3, NS4, and NS5) proteins of HCV. None of the inoc-
ulated animals showed humoral immune responses (i.e.,
production of specific antibodies) to any of these viral
proteins encoded by HCV.
It is intriguing that I-E2715 does not bind to peripheral
blood cells except PMN, which lack endogenous CD81
expression (Tedder et al., 1995). Although mouse CD81
does not bind HCV (Pileri et al., 1998), we could not
FIG. 2. Expression of the human CD81 protein in the liver of transgenic mice. Cryostat specimens were prepared from human CD81 transgenic
(panels a and b) nontransgenic mice (panel c). The specimens were pretreated with F(ab) of goat anti-mouse serum. Remaining unblocked mouse
immunoglobulins were visualized as blue color. The specimens were further stained with anti-mouse immunoglobulin only (panel a) or anti-human
CD81 plus anti-mouse immunoglobulin (panels b and c). The positive binding was visualized as red color. Original magnification, 400.
FIG. 4. Binding of I-E2715 to the liver of transgenic mice. Cryostat specimens were prepared from a nontransgenic (panel a) and human CD81
transgenic mice (panels b and c). These specimens were incubated with I-E2715 followed by anti-HCV serum from immunized chimpanzee. One
specimen was preincubated with anti-human CD81 prior to addition of I-E2715 (panel c). The positive binding was visualized as red color. The
specimens were also counterstained with hematoxylin. Original magnification, 400.
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exclude the possibility that endogenous CD81 might
compete with human CD81 to form a molecular complex
that allows the HCV-E2 glycoprotein to bind and function
as a receptor for HCV on PBL. To test this hypothesis, we
bred the human CD81 transgenic mice with CD81-defi-
cient (CD81/) mice (Maecker and Levy, 1997) and in-
oculated these animals too with HCV infectious plasma.
Again, there was no evidence of replication of HCV in the
CD81/ mice expressing human CD81. After this exper-
iment, we analyzed spleen cells from the inoculated mice
to confirm that the animals lacked endogenous CD81
expression (Fig. 6A).
We also checked the phenotype of these animals. PBL
from the mice still failed to bind I-E2715 (Fig. 6B, a and b),
while thymocytes from the same animals could bind
I-E2715 (Fig. 6B, c). These observations indicated that
coexpression of endogenous CD81 is not responsible for
failure of HCV to infect human CD81 transgenic mice.
DISCUSSION
We have proposed that human CD81 is a putative HCV
receptor because we demonstrated that human CD81
could bind bona fide HCV particles (Pileri et al., 1998).
Other groups have suggested the low-density lipoprotein
receptor (LDLR) as another candidate for the HCV recep-
tor (Agnello et al., 1999; Monazahian et al., 1999;
Wunschmann et al., 2000), although there is contradic-
tory evidence that a patient with familial hypercholester-
olemia, who had a deficiency of LDLR, was infected with
HCV (Marson et al., 1999), showing that if LDLR is a
receptor for HCV, it is not the only one. To date, the
importance of CD81 cannot be assessed by such an
epidemiologic survey because no individual with CD81
deficiency has been reported in the human population.
Lack of CD81 expression in humans may not bring about
recognizable clinical symptoms, similarly to mice, where
CD81 deficiency only leads to mild impairment of im-
mune responses (Maecker and Levy, 1997; Miyazaki et
al., 1997; Tsitsikov et al., 1997).
Although it has been reported that a number of cell
lines support HCV infection in vitro (Bertolini et al., 1993;
Cribier et al., 1995; Dash et al., 1997; Fournier et al., 1998;
Iacovacci et al., 1997; Ikeda et al., 1998; Kato et al., 1998;
Lanford et al., 1994; Morrica et al., 1999; Seipp et al.,
FIG. 3. Human CD81 expression in lymphoid tissues of transgenic mice. (A) Histogram showing binding of anti-human CD81 antibody on
splenocytes (panel a) and thymocytes (panel b). The x- and y-axes indicate the fluorescent antibody molecules bound to the cell surface and the
relative cell number, respectively. Patterns of the antibody binding to the cells from transgenic and nontransgenic mice are indicated as solid and
broken lines, respectively. (B) The two-dimensional dot-plot with forward and side scatters is used to distinguish between lymphocytes (small
cell-size  small forward scatter, round-shaped nucleus  small side scatter) (R1) and polymorphonuclear cells (PMN) (large cell-size  large
forward scatter, irregular-shaped nucleus  large side scatter) (R2) of mouse peripheral blood cells (panel a). The antibody binding on PBL and PMN
is drawn as histograms (panels b and c) by selecting cells within R1 and R2 (panel a), respectively. Patterns of the antibody binding to the cells from
transgenic and nontransgenic mice are indicated as solid and broken lines, respectively.
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1997; Shimizu et al., 1998; Shimizu and Yoshikura, 1994;
Tagawa et al., 1995; Valli et al., 1995), none of them have
been used to examine the importance of human CD81 in
HCV infection, probably because of technical difficulties.
Mice transgenic for human CD81 were considered to
offer a possibility to study the involvement of the putative
receptor during HCV infection in vivo. We addressed the
question of whether expression of human CD81 in trans-
genic mice confers susceptibility to HCV infection in vivo.
We produced transgenic mice expressing human CD81
ubiquitously. Expression of human CD81 did not cause
gross differences in mouse development, including lym-
phopoiesis. We inoculated HCV into these transgenic
mice intravenously or intrahepatically. Even though we
used high doses (20–2000 CID50) of infectious plasma,
no animals showed evidence of viral replication.
Because CD81, similar to other tetraspanin molecules,
forms molecular complexes with different molecules on
various type of cells (reviewed in Levy et al., 1998;
Maecker et al., 1997), the presence of the mouse CD81
molecule might reduce the chance for human CD81 to
form a “functional” receptor together with appropriate
molecules. We addressed the question of whether a
possible competition between the human CD81 mole-
cule and the mouse counterpart might account for the
failure of HCV to infect transgenic mice. Although the
endogenous mouse CD81 molecule does not bind HCV
(Pileri et al., 1998), it might compete with human CD81 to
form a functional receptor complex for internalization of
the virus. In addition, in our previous work, we observed
that the crystallized LEL of CD81 formed homodimers
(Kitadokoro et al., 2001) and such a homodimer may also
form in the cell surface as a receptor. If this were the
case, it would be likely that a human–mouse chimeric
CD81 dimer complex is formed on the transgenic cells.
Although we do not know the stoichiometry of CD81-E2
interaction, such a chimeric dimer may be inactive as a
receptor. To test this hypothesis, we also transferred the
transgene to CD81-deficient mice (Maecker and Levy,
1997). These mice, however, were also refractory to HCV
infection.
Taken together, these data show that expression of the
human CD81 molecule alone in mice is insufficient for
conferring susceptibility to HCV infection. There are sev-
eral possible reasons expression of human CD81 in mice
failed to confer susceptibility to HCV infection: (1) A
FIG. 5. E2 binding to lymphocytes of transgenic mice. (A) Histogram showing binding of I-E2715 on splenocytes (panel a) and thymocytes (panel b).
The x- and y-axes indicate the fluorescent protein bound to the cell surface and the relative cell number, respectively. Patterns of the I-E2715 binding
to the cells from transgenic and nontransgenic mice are indicated as solid and broken lines, respectively. (B) The two-dimensional dot-plot with
forward and side scatters is used to distinguish between lymphocytes (small cell-size  small forward scatter, round-shaped nucleus  small side
scatter) (R1) and polymorphonuclear cells (PMN) (large cell-size large forward scatter, irregular-shaped nucleus large side scatter) (R2) of mouse
peripheral blood cells (panel a). The I-E2715 binding on PBL and PMN is drawn as histograms (panels b and c) by selecting cells within R1 and R2
(panel a), respectively. Patterns of the I-E2715 binding to the cells from transgenic and nontransgenic mice are indicated as solid and broken lines,
respectively.
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second receptor is required. It has been reported that
CD81 from the cotton-top tamarin (Saguinus oedipus)
binds the E2 protein of HCV even better than human
CD81 (Allander et al., 2000; Meola et al., 2000), although
this primate is refractory to HCV infection (Garson et al.,
1997). In addition, we reported that cross-linking of CD81
on the human cells induces only minimal internalization
of the CD81 protein (Petracca et al., 2000). These findings
suggest that an additional molecule may be required for
entry of the virus particle into the target cell. (2) A certain
organ or a cell type (e.g., PBL) that fails to bind HCV-E2
in the transgenic mice is a crucial site for HCV replica-
tion. Unexpectedly, we observed that the E2 glycoprotein
of HCV, which may serve as a ligand for human CD81, did
not bind to lymphocytes in peripheral blood, although the
transgene product was detected on these cells by a
specific antibody to human CD81. This suggests that
mouse molecules forming complexes with the human
CD81 protein mask the binding site of the E2 glycopro-
tein on the surface of certain cell types. (3) The life cycle
of HCV requires some species-specific intracellular fac-
tor(s). To date, it is difficult to determine which of the
circumstances outlined above is true without a robust in
vitro culture system.
Finally, it is of interest to consider the existence of
molecules protecting from viral infection. For example,
the interferon-inducible Mx1 protein is known to protect
wild mouse strains from influenza virus infection (re-
viewed in Arnheiter and Meier, 1990). The presence of a
resistance gene against replication of HCV in Mus mus-
culus would on the one hand preclude using the trans-
genic mice system for HCV infection. On the other hand,
identification of such gene products would be of great
value not only for fundamental understanding of HCV
biology but also for development of preventive or thera-
peutic strategies for HCV infection.
MATERIALS AND METHODS
Construction of human CD81 transgene and
production of transgenic mice
A 1-kb fragment of human CD81 cDNA (Pileri et al.,
1998) was inserted between the 0.64-kb BamHI-EcoRI
fragment containing the second intron and the 0.56-kb
EcoRI-PvuII fragment containing the third exon including
the polyadenylation signal of the rabbit -globin gene
(Fig. 7A). This transcription unit of the transgene was
joined with the 1.6-kb regulatory unit of pCAGGS (Niwa et
FIG. 6. Expression of CD81 and E2 binding in hCD81mCD81/ mice. (A) Lack of endogenous CD81 expression in hCD81mCD81/ mice was
confirmed on splenocytes with the Eat2 monoclonal antibody. The x- and y-axes indicate the fluorescent antibody molecules bound to the cell surface
and the relative cell number, respectively. (B) Expression of human CD81 transgene expression (panel a), E2 binding (panel b) on PBL, and E2 binding
on thymocytes (panel c). The x- and y-axes indicate the fluorescent antibody molecules (panel a)/the recombinant proteins (panels b and c) bound
to the cell surface, and the relative cell number, respectively. Histograms of hCD81mCD81/ and hCD81mCD81 animals are indicated as solid
and broken lines, respectively. The histograms of a negative control animal (hCD81mCD81/) are shaded.
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al., 1991) (Fig. 7B). The 3.8-kb fragment including the CAG
regulatory unit and human CD81 transcription unit puri-
fied from this plasmid was used for zygote pronuclear
microinjection. The transgenes were microinjected into
zygotes of the FVB mouse by a commercial transgenic
animal production service (Eurogentech Bel S.A., Sera-
ing, Belgium).
Transgenic animals were identified by PCR to detect
transgene integration in genomic DNA from tail biopsies.
The tail DNA was prepared using DNeasy Tissue Extrac-
tion Kit (Qiagen). An aliquot of extracted DNA was sub-
mitted to a 20-l PCR. The reaction mixture contained
1 PCR buffer (67 mM Tris–HCl pH 8.8, 16.6 mM ammo-
nium sulfate, 2 mM MgCl2, 0.2 mM deoxyribonucleotide
mix, 0.1 mg/ml bovine serum albumin), 0.1 units Taq
platinum polymerase (Life Technologies), and 5 pmol
each of the TA5 and TA3 primers (Table 1, Fig. 7A).
The reaction mixture was incubated at 94°C for 10 min
followed by 35 cycles of a one-step PCR (30 s/94°C, 1
min/60°C, and 1 min/72°C) using a GeneAmp PCR Sys-
tem 9700 (Perkin–Elmer Applied Biosystems). The reac-
tion was further chased by incubation at 72°C for 15 min.
Ten microliters of the reaction mixture was analyzed by
agarose gel electrophoresis.
Positive founder animals were further crossed with
C57Bl/6 mice. Offspring positive for the transgene seg-
regation was monitored by PCR as described above.
FIG. 7. Strategy to construct the human CD81 transgene. (A) Transcription unit of human CD81. The partial rabbit -globin gene containing the 2nd
intron and the 3rd exon was split and used for splicing and polyadenylation sites to ensure efficient transcription of the transgene. The intron is
indicated as an open bar. The nontranslated exon and the human CD81-coding region are indicated as hatched and closed bars, respectively. The
PCR primers to detect transgene integration in the mouse genome (TA5 and TA3) are indicated as small arrows (not drawn to scale). (B) Construction
of the transgene. The CAG regulatory unit (indicated as a shaded bar) was joined at the 5 end of the transcription unit.
TABLE 1
PCR Primers Used in This Study
Primer Sequence Positiona
TA5 5-ACCTGCTCTTCGTCTTCAATTTCG 273–296
TA3 5-GTACACGGAGCTGTTCCGGATGCC 923–900
162AS 5-GATGCACGGTCTACGAGACCTC 341–320
163S 5-AACTACTGTCTTCACGCAGAA 53–73
164AS 5-GCGACCCAACACTACTCGGCT 272–252
165S 5-ATGGCGTTAGTATGAGTG 85–102
a The positions of the human CD81 cDNA (for primers TA5 and TA3)
and the HCV genomic RNA (for primers 162SA, 163S, 164AS, and 165S)
are adapted from the GenBank nucleotide database Accession Nos.
NM_004356 and D45172, respectively.
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Two lines were also crossed with CD81 knockout mice
(Maecker and Levy, 1997). Homozygosity of the CD81-
deficient allele was checked by Southern blot hybridiza-
tion (Sambrook et al., 1989) using a mouse CD81-specific
DNA probe.
Northern blot hybridization
Total RNA from various organs of mice was isolated
using Trizol Reagent (Life Technologies). Ten to thirty
micrograms of RNA were separated on a formaldehyde-
agarose gel. RNA was transferred to a Hybond mem-
brane (Amersham) and hybridized with a 32P-labeled hu-
man CD81 cDNA probe using a standard protocol (Sam-
brook et al., 1989). Hybridized radioactivity on the
membrane was visualized on a PhosphorImager (Molec-
ular Dynamics).
Immunohistochemistry
Cryostat liver sections of 3 m thickness were fixed in
acetone at room temperature for 10 min. Before staining
with JS81, the mouse tissue was blocked by preincuba-
tion with F(ab)2 fragments derived from goat anti-mouse
immunoglobulin (Cappel) (1/10,000 dilution in 50 mM
Tris-buffered saline, TBS) for 30 min. After rinsing with
TBS for 10 min, the sections were incubated with rabbit
anti-mouse serum (Dako, Z259) (1/30 dilution in TBS) for
30 min, followed by alkaline phosphatase anti-alkaline
phosphatase (APAAP) immunocomplex (Dako) (1/50 di-
lution in TBS) for 30 min. The residual unblocked mouse
tissue Ig was then developed in blue using naphthol-
AS-BI phosphate (Aldrich) as a substrate and Fast Blue
BB salt (Aldrich) as a chromogen. After this treatment, the
liver section was incubated with JS81 (0.5 mg/ml) (1/50 to
1/400 dilution in TBS) at room temperature for 1 h. The
specimen was again incubated with the rabbit anti-
mouse serum and treated with APAAP immunocomplex
as described above. The positive staining was devel-
oped in red color with naphthol-AS-BI phosphate as a
substrate, and New Fuchsin (Dako) as a chromogen.
To detect E2 binding, the procedure to develop blue
color was omitted because no antibody against mouse
immunoglobulins was used. The preincubated specimen
was incubated with 30 g/ml I-E2715 and subsequently
with anti-HCV chimpanzee serum (20 g/ml as protein
concentration) and with alkaline phosphatase conju-
gated goat anti-human immunoglobulins (Cappel) (1/200
dilution in TBS). Each incubation step was performed at
room temperature for 30 min, followed by a 10-min rins-
ing step with TBS. E2 binding was developed in red color
as described above. In some experiments, an incubation
step with JS81 (1/50 dilution in TBS) was inserted before
I-E2715 incubation for specific blocking. The specimens
for E2 binding were also counterstained with hematoxy-
lin.
Cytofluorometric analysis
Splenocytes, thymocytes, and peripheral blood leuko-
cytes were washed once with cold washing buffer (phos-
phate-buffered saline supplemented with 5% fetal calf
serum). For detecting transgene expression, the cells
were incubated with phycoerythrin (PE)-conjugated JS81
(Pharmingen), a monoclonal antibody specific for human
CD81. Mouse CD81 was detected by incubating lympho-
cytes with biotinylated Eat2 (Pharmingen), a monoclonal
antibody specific for mouse CD81 (Maecker et al., 2000),
and PE-conjugated streptavidin (Johnson Immuno-
Research Laboratories). For E2 binding assay, the cells
were treated with the recombinant I-E2715 protein (Heile
et al., 2000), biotinylated 291A2 (a monoclonal antibody
specific for E2) (Rosa et al., 1996), and PE-conjugated
streptavidin. CD81 expression and I-E2715 binding were
detected on FACScan (Becton–Dickinson) or FACS Cali-
ber (Becton–Dickinson). The acquired data were ana-
lyzed with the CellQuest program (Becton–Dickinson).
Infection assay
All animals engaged in infection experiments were
housed in the infectious disease isolation facility under
European Community law conditions at the Department
of Biomedicine, University of Pisa. Transgenic mice and
normal littermates were submitted to infection experi-
ments. Each type of mice was divided into four groups of
three or four animals. Each group was challenged either
intravenously or intrahepatically with diluted infectious
chimpanzee plasma containing various doses (20–2000
CID50) of HCV virions. Every month after inoculation,
plasma was taken from animals to extract RNA using
High Pure Viral Nucleic Acid (Boehringer Mannheim).
The purified RNA was submitted to HCV-specific nested
PCR. Human serum infected with HCV was used as a
positive control for detection of the HCV-specific se-
quence. Five microliters of extracted RNA was reverse-
transcribed at 42°C for 60 min in a 15 l of reaction
cocktail with the 162AS primer (Table 1) in the presence
of 20 units of RNase inhibitor (Boehringer Mannheim), 2
mM deoxyribonucleic acid mixture, 3 units of avian my-
eloblastosis virus (AMV) reverse transcriptase (Promega)
with its accompanying buffer. The reverse-transcription
reaction was terminated by incubating at 94°C for 5 min.
The cDNA was then directly amplified in a 40 l reaction
mix containing the appropriate PCR buffer with the 163S
primer (Table 1) and Taq DNA polymerase (1.25 units)
under the following conditions: five cycles of 94°C 60 s,
55°C 60 s, 72°C 90 s, followed by 30 cycles of 94°C 45 s,
55°C 30 s, 72°C 60 s. Five microliters of the first-step
amplification reaction was submitted to the second PCR
with the 164AS and 165S primers (Table 1) and freshly
added Taq DNA polymerase (1.25 units) in a 50 l reac-
tion volume under the following conditions: five cycles of
94°C 60 s, 55°C 45 s, 72°C 90 s, followed by 20 cycles
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of 94°C 30 s, 55°C 30 s, 72°C 60 s. A chase step (72°C
15 min) followed at the end of the PCR. Ten microliters of
the reaction mixture was analyzed by agarose gel elec-
trophoresis.
Anti-HCV antibody assay
HCV-specific antibodies were measured by ELISA and
Western blot analysis. For these experiments, 5 months
postinfection mouse plasma was used. For ELISA,
plasma diluted to 1:20 was submitted to Ortho HCV 3.0
ELISA Test System (Ortho-Clinical Diagnostics GmbH). A
human HCV-positive serum and normal mouse plasma
were used as positive and negative controls, respec-
tively. For Western blot, 50–75 g of human superoxide
dismutase (SOD)-conjugated recombinant HCV proteins
(C22-3, C33C, C100-3, NS5) and recombinant human
SOD (negative control) were electrophoresed on a 12%
polyacrylamide gel in denaturing and reducing condi-
tions. After the separated antigens in the gel were trans-
ferred onto a nitrocellulose membrane as described (Fre-
er et al., 1998), the membrane was pretreated and incu-
bated with diluted plasma (1/20 dilution in TBS
supplemented with 5% bovine serum albumin) to detect
the presence of HCV-specific antibodies. The presence
of HCV-specific antibodies was visualized with horserad-
ish peroxidase labeled goat anti-mouse IgG (or anti-
human for the positive control) and diaminobenzidine.
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